People living with sickle cell disease need frequent blood transfusion to manage their condition. Spectra Optia separates and removes sickle shaped red blood cells from patients’ blood and replaces it with healthy red blood cells. The system is faster, needs to be repeated less frequently and does not add iron in the same way as manual exchange. NICE guidance MTG28.

Project overview

The Spectra Optia Apheresis System is an apheresis and cell collection platform for the treatment of sickle cell disease. In a typical exchange procedure, Spectra Optia separates and removes sickle red blood cells from the patient’s blood using continuous flow and centrifugation. These are replaced with healthy red blood cells according to the user-defined software protocol.

NICE guidance (MTG28) found that Spectra Optia saves NHS resources, when taking the costs of manual red blood cell exchange, top-up transfusion, chelation therapy (for iron overload) and non-elective hospital admissions into account.

Our aim is to support providers to secure funding for the on-going use of this technology through the MedTech Funding Mandate policy or expand its use.

Share: